- This event has passed.
Signatera for MRD detection in High-Risk Breast Cancer
December 7, 2021 @ 2:00 pm - 3:00 pm CST
Sponsored by Natera
There are many tools available to determine risk of recurrence in patients with breast cancer. Yet, there remains an unmet need for more sensitive, personalized tumor testing. Signatera can identify molecular residual disease in your patients at risk of recurrence through ultra-sensitive ctDNA detection. Come learn how Signatera can help you refine individualized risk assessment, personalize surveillance strategy, and understand whether immunotherapy treatment is working.